SG11201907607VA - Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor - Google Patents
Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitorInfo
- Publication number
- SG11201907607VA SG11201907607VA SG11201907607VA SG11201907607VA SG11201907607VA SG 11201907607V A SG11201907607V A SG 11201907607VA SG 11201907607V A SG11201907607V A SG 11201907607VA SG 11201907607V A SG11201907607V A SG 11201907607VA SG 11201907607V A SG11201907607V A SG 11201907607VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- responsive
- treatment
- turnhoutseweg
- beerse
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIP0 I PCT omit VIII °nolo OH 100 mil Holum oimIE (10) International Publication Number WO 2018/154104 Al (51) International Patent Classification: C12Q 1/48 (2006.01) G01N 33/574 (2006.01) C12Q 1/68 (2018.01) (21) International Application Number: PCT/EP2018/054644 (22) International Filing Date: 26 February 2018 (26.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/464006 27 February 2017 (27.02.2017) US (71) Applicant: JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE). (72) Inventors: BREHMER, Dirk; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). BEKE, Lijs; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). GAFFNEY, Dana, Suzanne; Janssen Research & Devel- opment, LLC, 920 US Route 202, PO Box 300, Raritan, NJ 08869 (US). MOY, Christopher, H; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Rar- itan, NJ 08869 (US). (74) Agent: VANDERSTEEN, Pieter; J&J Patent Law Depart- ment, Turnhoutseweg 30, 2340 Beerse (BE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) O 00 O C (54) Title: USE OF BIOMARKERS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR (57) : The present invention concerns a method of identifying a patient that is likely to be responsive to treatment with a protein arginine N-methyltransferase 5 (PRMT5) inhibitor comprising: evaluating a biological sample from the patient for the presence of a spliceosome alteration, wherein the presence of any said alteration indicates a higher likelihood for said patient to be responsive to treatment with said PRMT5 inhibitor than in the absence of any said mutation or alteration.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762464006P | 2017-02-27 | 2017-02-27 | |
PCT/EP2018/054644 WO2018154104A1 (en) | 2017-02-27 | 2018-02-26 | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907607VA true SG11201907607VA (en) | 2019-09-27 |
Family
ID=61563368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907607VA SG11201907607VA (en) | 2017-02-27 | 2018-02-26 | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
Country Status (22)
Country | Link |
---|---|
US (2) | US11279970B2 (en) |
EP (1) | EP3585904B1 (en) |
JP (1) | JP7225106B2 (en) |
KR (1) | KR102573149B1 (en) |
CN (1) | CN110382707A (en) |
AU (1) | AU2018225312B2 (en) |
BR (1) | BR112019017466A2 (en) |
CA (1) | CA3049739A1 (en) |
CL (1) | CL2019002438A1 (en) |
CO (1) | CO2019008390A2 (en) |
EA (1) | EA201992026A1 (en) |
IL (1) | IL268842A (en) |
JO (1) | JOP20190199B1 (en) |
MA (1) | MA47594A (en) |
MX (1) | MX2019010150A (en) |
MY (1) | MY195860A (en) |
PE (1) | PE20191359A1 (en) |
PH (1) | PH12019501942A1 (en) |
SG (1) | SG11201907607VA (en) |
TN (1) | TN2019000212A1 (en) |
UA (1) | UA127679C2 (en) |
WO (1) | WO2018154104A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI791251B (en) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors |
ES2891320T3 (en) | 2016-03-10 | 2022-01-27 | Janssen Pharmaceutica Nv | Substituted nucleoside analogs for use as PRMT5 inhibitors |
UA124074C2 (en) | 2016-10-03 | 2021-07-14 | Янссен Фармацевтика Нв | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
KR102573149B1 (en) | 2017-02-27 | 2023-08-30 | 얀센 파마슈티카 엔.브이. | Use of Biomarkers in the Identification of Cancer Patients Responsive to Treatment with PRMT5 Inhibitors |
EP3720495A4 (en) * | 2017-12-05 | 2021-06-02 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as prmt5 inhibitors |
WO2019110734A1 (en) | 2017-12-08 | 2019-06-13 | Janssen Pharmaceutica Nv | Novel spirobicyclic analogues |
IL262658A (en) * | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
SG11202110742TA (en) | 2019-04-02 | 2021-10-28 | Aligos Therapeutics Inc | Compounds targeting prmt5 |
GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
TW202112375A (en) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | Methods of treating cancer using prmt5 inhibitors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
CN1331326A (en) * | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | Polypeptide-human arginine methyltransferase (HRMT) 32.12 and polynucleotide for coding it |
AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
RU2317994C2 (en) | 2002-02-19 | 2008-02-27 | Си Ви Терапьютикс, Инк. | Partial and complete agonists of adenosine a1 receptors |
US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
EP1645561A1 (en) | 2003-07-15 | 2006-04-12 | Mitsui Chemicals, Inc. | Method of synthesizing cyclic bisdinucleoside |
CA2548283A1 (en) | 2003-12-19 | 2005-07-21 | Koronis Pharmaceuticals, Inc. | Mutagenic heterocycles |
EP1844062A2 (en) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
US20110159111A1 (en) | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
AU2009298802A1 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
US8323918B2 (en) * | 2008-12-12 | 2012-12-04 | University Of South Carolina | Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases |
EA201270661A1 (en) | 2009-12-18 | 2013-06-28 | Президент Энд Феллоуз Оф Гарвард Колледж | REINFORCING THE REPLACEMENT OF β-CELL CONNECTIONS AND METHODS OF THEIR APPLICATION |
US9145438B2 (en) | 2010-12-03 | 2015-09-29 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
CA2819620A1 (en) | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
EP2651885A1 (en) | 2010-12-16 | 2013-10-23 | Abbvie Inc. | Anti-viral compounds |
EP2694524B1 (en) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides |
US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
JP6678455B2 (en) | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | PRMT5 inhibitors and uses thereof |
CA2894130A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
JP2016505000A (en) | 2012-12-21 | 2016-02-18 | エピザイム,インコーポレイティド | PRMT5 inhibitors and uses thereof |
CA2935944A1 (en) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
JP6603712B2 (en) | 2014-07-01 | 2019-11-06 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Heteroaryl compounds useful as inhibitors of SUMO activating enzymes |
AU2016225133B2 (en) | 2015-02-24 | 2018-11-29 | Pfizer Inc. | Substituted nucleoside derivatives useful as anticancer agents |
TWI791251B (en) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors |
EP3426664B1 (en) | 2016-03-10 | 2021-06-30 | Janssen Pharmaceutica NV | Substituted nucleoside analogues for use as prmt5 inhibitors |
EA201990851A1 (en) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | NEW CARBANUCLEOSIDE ANALOGUES REPLACED BY MONOCYCLIC AND BICYCLIC RING SYSTEM FOR USE AS PRMT5 INHIBITORS |
KR102573149B1 (en) | 2017-02-27 | 2023-08-30 | 얀센 파마슈티카 엔.브이. | Use of Biomarkers in the Identification of Cancer Patients Responsive to Treatment with PRMT5 Inhibitors |
-
2018
- 2018-02-26 KR KR1020197024211A patent/KR102573149B1/en active IP Right Grant
- 2018-02-26 PE PE2019001538A patent/PE20191359A1/en unknown
- 2018-02-26 MA MA047594A patent/MA47594A/en unknown
- 2018-02-26 EA EA201992026A patent/EA201992026A1/en unknown
- 2018-02-26 CA CA3049739A patent/CA3049739A1/en active Pending
- 2018-02-26 TN TNP/2019/000212A patent/TN2019000212A1/en unknown
- 2018-02-26 JP JP2019545251A patent/JP7225106B2/en active Active
- 2018-02-26 US US16/487,852 patent/US11279970B2/en active Active
- 2018-02-26 UA UAA201910005A patent/UA127679C2/en unknown
- 2018-02-26 BR BR112019017466-4A patent/BR112019017466A2/en unknown
- 2018-02-26 AU AU2018225312A patent/AU2018225312B2/en active Active
- 2018-02-26 MY MYPI2019004748A patent/MY195860A/en unknown
- 2018-02-26 EP EP18708634.3A patent/EP3585904B1/en active Active
- 2018-02-26 MX MX2019010150A patent/MX2019010150A/en unknown
- 2018-02-26 JO JOP/2019/0199A patent/JOP20190199B1/en active
- 2018-02-26 SG SG11201907607VA patent/SG11201907607VA/en unknown
- 2018-02-26 WO PCT/EP2018/054644 patent/WO2018154104A1/en active Application Filing
- 2018-02-26 CN CN201880013998.5A patent/CN110382707A/en active Pending
-
2019
- 2019-07-31 CO CONC2019/0008390A patent/CO2019008390A2/en unknown
- 2019-08-22 PH PH12019501942A patent/PH12019501942A1/en unknown
- 2019-08-22 IL IL26884219A patent/IL268842A/en unknown
- 2019-08-23 CL CL2019002438A patent/CL2019002438A1/en unknown
-
2022
- 2022-02-10 US US17/669,008 patent/US20220205026A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3585904B1 (en) | 2023-11-29 |
BR112019017466A2 (en) | 2020-03-31 |
JP2020508048A (en) | 2020-03-19 |
EP3585904C0 (en) | 2023-11-29 |
IL268842A (en) | 2019-10-31 |
CL2019002438A1 (en) | 2019-11-29 |
CA3049739A1 (en) | 2018-08-30 |
KR102573149B1 (en) | 2023-08-30 |
AU2018225312A1 (en) | 2019-07-25 |
UA127679C2 (en) | 2023-11-29 |
MX2019010150A (en) | 2019-10-21 |
JP7225106B2 (en) | 2023-02-20 |
CN110382707A (en) | 2019-10-25 |
MY195860A (en) | 2023-02-24 |
CO2019008390A2 (en) | 2019-08-20 |
PE20191359A1 (en) | 2019-10-01 |
US20200010881A1 (en) | 2020-01-09 |
US11279970B2 (en) | 2022-03-22 |
KR20190122677A (en) | 2019-10-30 |
MA47594A (en) | 2020-01-01 |
US20220205026A1 (en) | 2022-06-30 |
WO2018154104A1 (en) | 2018-08-30 |
EA201992026A1 (en) | 2020-01-24 |
JOP20190199A1 (en) | 2019-08-27 |
AU2018225312B2 (en) | 2024-02-08 |
PH12019501942A1 (en) | 2020-06-29 |
JOP20190199B1 (en) | 2023-09-17 |
EP3585904A1 (en) | 2020-01-01 |
TN2019000212A1 (en) | 2021-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907607VA (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201809913PA (en) | Methods for detecting target nucleic acids in a sample | |
SG11201805157TA (en) | Targeted disruption of the mhc cell receptor | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
SG11201909656YA (en) | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | |
SG11201903958SA (en) | Intuitive occluded object indicator | |
SG11201906765UA (en) | Personalised immunogenic peptide identification platform | |
SG11201908767QA (en) | Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy | |
SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
SG11201408385TA (en) | Methods of detecting diseases or conditions | |
SG11201805906WA (en) | Diagnostic and prognostic methods for cardiovascular diseases and events | |
SG11201408383SA (en) | Methods of detecting diseases or conditions using circulating diseased cells | |
SG11201910195WA (en) | Methods for trapping and barcoding discrete biological units in hydrogel | |
SG11201910206QA (en) | Methods and compositions for treating inflammatory gastrointestinal disorders | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11201806852PA (en) | Protein purification | |
SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
SG11201408434QA (en) | Targeted rna-seq methods and materials for the diagnosis of prostate cancer |